Phase II trial of BI 187004 (VTP-34072) in patients with type 2 diabetes mellitus

Trial Profile

Phase II trial of BI 187004 (VTP-34072) in patients with type 2 diabetes mellitus

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2015

At a glance

  • Drugs BI 187004 CL (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Proof of concept; Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 17 Dec 2015 According to Vitae media release, company anticipated based on these earlier results, in this remaining monotherapy arm of the trial, BI187004 did not achieve the predefined primary efficacy endpoint criteria and hence, Boehringer Ingelheim has informed Vitae of its intention to terminate the program and its corresponding license agreement.
    • 17 Dec 2015 Results published in Vitae Pharmaceuticals media release.
    • 04 Aug 2015 Top-line efficacy results from the metformin arm have been reported, according to a Vitae Pharmaceuticals media release. Results from the ongoing, placebo-controlled monotherapy arm are expected to be reported later in 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top